Last Price
6.33
Today's Change
-0.17 (2.61%)
Day's Change
6.22 - 6.56
Trading Volume
1,034,357
Overview
Market Cap
2 Billion
Shares Outstanding
319 Million
Avg Volume
2,041,146
Avg Price (50 Days)
7.29
Avg Price (200 Days)
4.65
PE Ratio
-39.56
EPS
-0.16
Earnings Announcement
22-Nov-2024
Previous Close
6.50
Open
6.54
Day's Range
6.22 - 6.56
Year Range
0.975 - 8.975
Trading Volume
1,034,679
Price Change Highlight
1 Day Change
-2.62%
5 Day Change
-9.70%
1 Month Change
-15.37%
3 Month Change
8.21%
6 Month Change
133.58%
Ytd Change
200.00%
1 Year Change
526.73%
3 Year Change
475.45%
5 Year Change
322.00%
10 Year Change
322.00%
Max Change
322.00%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Apps
Top Articles
1
CEO Morning Brief
Hyundai India Starts US$3.3b IPO in Country's Largest-ever Share Sale
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
